Seoul, South Korea

Chan-Hwa Kim

This inventor holds 1 USPTO granted patent. Top assignee: M.i.tech Co., Ltd.. Active years: 2006.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Chan-Hwa Kim. Retrieved from https://idiyas.com/inventor/chan-hwa-kim

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 11(Granted Patents)


Company Filing History:


Years Active: 2006

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations in Insulin Delivery by Chan-Hwa Kim

Introduction

Chan-Hwa Kim is a notable inventor based in Seoul, South Korea. He has made significant contributions to the field of pharmaceutical preparations, particularly in the controlled release of insulin. His innovative approach aims to enhance the stability and efficacy of insulin delivery systems.

Latest Patents

One of Chan-Hwa Kim's key patents is titled "Controlled release preparation of insulin and its method." This patent describes a controlled release preparation that utilizes microparticles obtained through the microencapsulation of uniform microcrystals of insulin using biodegradable polymeric materials. The method reduces the denaturation of insulin during microencapsulation, thereby increasing the stability of the preparation. Additionally, the ratio of insulin to the polymer carrier is optimized for pulmonary delivery, allowing for continuous pharmaceutical efficacy in vivo over an extended period.

Career Highlights

Chan-Hwa Kim is associated with M.i.tech Co., Ltd., where he continues to develop innovative solutions in drug delivery systems. His work has garnered attention for its potential to improve the management of diabetes through more effective insulin delivery methods.

Collaborations

He collaborates with talented individuals such as Jai-Hyun Kwon and Sung-Hee Choi, who contribute to the advancement of his research and innovations.

Conclusion

Chan-Hwa Kim's work in the controlled release of insulin represents a significant advancement in pharmaceutical technology. His innovative methods promise to enhance the stability and effectiveness of insulin delivery, ultimately benefiting patients with diabetes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…